Molecular Express, Inc.
Compton, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 2630 Homestead Pl, Compton, CA 90220, USA
- Website
- molecularexpress.com
- Founded
- 1996
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $4,999,218 |
| FY2023 | $580,061 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | U19AI189178 | $418,494 |
Similar vendors
About the company
Molecular Express, Inc. is a minority-owned, self-certified small disadvantaged business specializing in innovative drug formulations, therapeutics, and vaccine technologies primarily focused on infectious diseases and respiratory health solutions. Registered in SAM.gov since 2004, the company develops advanced liposomal platforms and pharmaceutical formulations for various medical applications, with a particular emphasis on creating synthetic drug delivery systems and vaccine technologies that address unmet medical needs.
Through federal contract awards, Molecular Express has consistently secured contracts with the National Institute of Allergy and Infectious Diseases (NIAID) to develop advanced medical technologies. Their contract work has primarily focused on HIV vaccine research, including engineering novel HIV GP41 ectodomain antigens, developing Vesivax liposomal platforms for antigen delivery, and designing HIV immunogen formulations. The contracts are predominantly Small Business Innovation Research (SBIR) Program Phase I and Phase II awards, with total small business set-asides ranging from $300,000 to nearly $3 million. These contracts involve developing innovative vaccine technologies, co-adjuvant formulations, and exploring different delivery methods for infectious disease treatments, consistently working to advance medical research through their specialized technological platforms.
The company's federal grant awards have been similarly focused on advanced medical research, with significant work in developing synthetic lung surfactants and innovative treatments for respiratory conditions. Grants from the National Heart, Lung, and Blood Institute (NHLBI) and NIAID have supported projects such as preclinical development of ME-1001, a fully synthetic lung surfactant for treating neonatal respiratory distress syndrome, and exploring niclosamide formulations for treating influenza infections. These grant-funded projects aim to create cost-effective medical solutions with potentially transformative impacts on global public health, particularly in addressing critical medical challenges in respiratory medicine and infectious disease treatment. The grants range from approximately $300,000 to $1 million and are primarily structured as Project Grants under specific research programs targeting cardiovascular diseases and infectious disease interventions.
SBA capabilities narrative
Research and development in molecular biology, vaccine research, delivery platform technologies.
Quick answers
Is Molecular Express, Inc. registered in SAM.gov?
Yes. Molecular Express, Inc.'s SAM.gov registration is active through October 22, 2027.
What is Molecular Express, Inc.'s CAGE code?
Molecular Express, Inc.'s CAGE code is 337D8, and its Unique Entity ID (UEI) is R1JMHFESEKD5.
How much has Molecular Express, Inc. received in federal contracts?
Federal contracts obligated $5,579,279 to Molecular Express, Inc. in fiscal years 2023 through 2027.
What is Molecular Express, Inc.'s most recent federal award?
Molecular Express, Inc.'s most recent federal contract award is Vesivax TLR7 formula (75N93024C00017), from National Institute of Allergy and Infectious Diseases (NIH), on September 1, 2024.
On GovTribe
See Molecular Express, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors